In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accentia Biopharmaceuticals Inc.

www.accentia.net

Latest From Accentia Biopharmaceuticals Inc.

BioVest names Eduardo Sotomayor to SAB

BioVest International, an emerging leader in active personalised immunotherapies and majority-owned subsidiary of Accentia Biopharmaceuticals, has named Dr Eduardo Sotomayor to its scientific advisory board. Dr Sotomayor currently serves as chair of the department of malignant hematology at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida.

Cancer

Biovest – from Chapter 11 to the edge of market filing in EU and Canada

After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and the US.

Cancer Canada

2010 Scrip 100 - Unleashing the power of the immune system to fight cancer

Recent developments in the field of active cancer immunotherapy foreshadow that the "next big thing" in cancer drugs may be on the way. Yet appropriately designed clinical trials testing combination approaches and continued understanding of the intricacies of the immune system will be needed to maximise benefits for patients, says Malini Guha.

Cancer Orthopedics

Personalised therapeutic cancer vaccine shows benefit in Phase III lymphoma trial

Biovest International's (Accentia Biopharmaceuticals) therapeutic cancer vaccine BiovaxID looks to have become the first to improve disease-free survival (DFS) in follicular lymphoma (FL) in the pivotal Phase III BV-301 study that was highlighted at a plenary session at the ASCO meeting in Orlando.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Accentia Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Accentia Biopharmaceuticals Inc.
  • Senior Management
  • Francis E O'Donnell, Jr., MD, CEO
    Alan M Pearce, CFO
  • Contact Info
  • Accentia Biopharmaceuticals Inc.
    Phone: (813) 864-2554
    324 South Hyde Park Ave.
    Ste. 350
    Tampa, FL 33606
    USA
UsernamePublicRestriction

Register